Clinical Trial Update: A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Roche-sponsored Phase 1/2 study evaluating multiple immunotherapy-based treatment combinations in HR-positive, HER2-negative breast cancer has completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Neoplasms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-11-10